Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;39(6):2502-2514.
doi: 10.1007/s12325-022-02120-6. Epub 2022 Mar 29.

Epidemiology and Economic Burden of Atopic Dermatitis: Real-World Retrospective Data from a Large Nationwide Israeli Healthcare Provider Database

Clara Weil  1 , Philip B Sugerman  2 , Gabriel Chodick  3   4 , Huifang Liang  2 , Hongwei Wang  2 , Brian M Calimlim  2 , Ana Dorfman  5 , Varda Shalev  3   4 , Dan Ben Amitai  4   6 , Yael A Leshem  4   7
Affiliations

Epidemiology and Economic Burden of Atopic Dermatitis: Real-World Retrospective Data from a Large Nationwide Israeli Healthcare Provider Database

Clara Weil et al. Adv Ther. 2022 Jun.

Erratum in

Abstract

Introduction: Real-world data on the epidemiology and economic burden of atopic dermatitis (AD) are limited. Here we describe the epidemiology and economic burden of AD using electronic healthcare data from Israel.

Methods: A retrospective study was performed using the Maccabi Healthcare Services database. AD incidence in 2008-2017 and point prevalence (ADprev) on 31 December 2017 were described using diagnosis codes for overall patients, and sex and age subgroups. For ADprev, severity was defined using recently dispensed treatments for AD. Annual healthcare resource utilization in AD prevalent patients was compared with non-AD matched controls using generalized linear modelling. Direct annual costs were estimated also.

Results: AD incidence was 7.0/1000 person-years; overall prevalence was 4.4% (female patients 4.5%, male patients 4.3%; age 0 to less than 6 months, 0.9%; 6 months to less than 12 years, 11.0%; 12 to less than 18 years, 5.8%; 18 years or older, 2.2%). Among ADprev (n = 94,483), mild, moderate, and severe AD comprised 57.7%, 36.2%, and 6.1% (adults 43.8%, 46.3%, 9.9%), respectively. Dermatologist and allergist visits and hospitalization rates (at least one) were 40.7%, 6.6%, and 3.8% in 2017. Compared with controls, overall and moderate-to-severe AD were associated with 36% and 52% increases in annual per-person costs (incremental costs $126 and $190).

Conclusions: AD epidemiology in Israel is comparable with other real-world database studies. AD imposes an economic burden that increases with disease severity.

Keywords: Atopic eczema; Epidemiology; Health economics.

Plain language summary

Occurrence and costs of atopic dermatitis in IsraelAtopic dermatitis is a disease that causes the skin to be inflamed and itchy. Atopic dermatitis is most common in children but can also occur in adolescents and adults. Using data from a large healthcare provider in Israel, this study aimed to describe how common atopic dermatitis is within the population. Costs related to the use of healthcare services (such as visits to dermatologists and creams to treat atopic dermatitis) in the year 2017 were compared between persons with versus without atopic dermatitis. For the years 2008 to 2017, approximately 7 out of 1000 people were newly diagnosed with atopic dermatitis each year (incidence). Among people alive on 31 December 2017, 4.4% had atopic dermatitis (prevalence), with 42.3% suggestive of moderate to severe disease. Patients with atopic dermatitis, particularly those with more severe disease, used healthcare services more frequently. Compared with people without atopic dermatitis, medical costs among patients with atopic dermatitis were 36% higher (corresponding to added costs of $126 per person per year). This study helps to better understand how many people have atopic dermatitis, and what healthcare resources are needed to manage this disease.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Atopic dermatitis: age- and sex-specific incidence in Israel* (2008–2017 average). AD atopic dermatitis, MHS Maccabi Healthcare Services, mo months; y years. *MHS is a nationwide healthcare insurer and provider with more than 2.3 million members in 2017
Fig. 2
Fig. 2
Atopic dermatitis: age-specific prevalence in Israel* by sex (31 December 2017). AD atopic dermatitis, MHS Maccabi Healthcare Services, mo months, y years. *MHS is a nationwide healthcare insurer and provider with more than 2.3 million members in 2017
Fig. 3
Fig. 3
Atopic dermatitis: HCRU in past year among AD prevalent patients (by severity)* and non-AD controls.† Note that high cost outliers were excluded. AD atopic dermatitis, ER emergency room, HCRU healthcare resource utilization, PCP primary care physician, SI systemic immunomodulators, SC systemic corticosteroids, TCI topical calcineurin inhibitor, TCS topical corticosteroids. *For comparison of AD by severity: n = 93,432. †For comparison of AD vs non-AD controls: n = 92,632 matched pairs
See this image and copyright information in PMC

References

    1. Bieber T. Atopic dermatitis. Ann Dermatol. 2010;22:125–137. doi: 10.5021/ad.2010.22.2.125. - DOI - PMC - PubMed
    1. Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74:491–498. doi: 10.1016/j.jaad.2015.10.043. - DOI - PubMed
    1. Williams H, Robertson C, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol. 1999;103:125–138. doi: 10.1016/S0091-6749(99)70536-1. - DOI - PubMed
    1. Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35:283–289. doi: 10.1016/j.det.2017.02.002. - DOI - PubMed
    1. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children’s Health. J Invest Dermatol. 2011;131:67–73. doi: 10.1038/jid.2010.251. - DOI - PMC - PubMed

Publication types

LinkOut - more resources